Behnood Bikdeli, MD, FACC
Associate physician
Brigham & Women's Medical Center

Printed as of 11/18/2026

Disclosures

Personal Commercial (2)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
AHA	Other - *Dr. Bikdeli is supported by a Career Development Award from the American Heart Association and VIVA Physicians (#938814).*	Significant (>= $5,000)	*Vascular Medicine*
NHLBI and Translational Sciences	Data Safety Monitoring Board	Modest (< $5,000)	*Vascular Medicine*

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (4)

Non-Commercial Enity Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
American Heart Association *† Validating efficient tools for identification of patients with pulmonary embolism in electronic databases*	Research/Research Grants	Significant (>= $5,000)	*Vascular Medicine*
Brigham and Women's Hospital *† Research grants related to COVID-19 associated thrombosis, and research grants related to sex-specific findings and sex differences for thrombotic diseases*	Research/Research Grants	Significant (>= $5,000)	*Vascular Medicine*
NATF *† No funds as a Medical Advisory Board Member. However, I prepare independent review summaries for which I get compensated.*	Other - *member of the Medical Advisory Board*	Significant (>= $5,000)	*Vascular Medicine*
NHLBI (Co-I for STAT-CAT trial)	Salary	Significant (>= $5,000)	*Vascular Medicine*

Clinical Trial Enroller (1)

Trial Name	Trial Sponsor	Trial Funding Source
HI-PRO	Bristol-Myers Squibb Company	

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (1)

Year	Case Title	Represented	Description	Compensation
Self				
2017	IVC filters	Plaintiff *† Patients and their attorneys (none for 2022 or 2023)*	Consulting expert, on behalf of the plaintiff, for litigation RE 2 brand models of IVC filters. He has not been involved in 2022 or 2023 nor has he received compensation in 2022 or 2023.	Significant (>= $5,000)

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 1/27/2026

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 1/27/2026

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 1/27/2026

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.